Skip to main content
Premium Trial:

Request an Annual Quote

IntregraGen Wins $2.5M Investment From DSM, Signs Molecular Dx Pact

NEW YORK (GenomeWeb News) — IntegraGen today said it has received a €2 million ($2.5 million) equity investment from DSM Venturing, with which it has also signed a research partnership to develop molecular diagnostics.
 
Under the terms of the agreement, IntegraGen will receive upfront fees, licensing fees, and funding to develop gene-based diagnostic and prognostic tests.
 
DSM, a branch of Royal DSM, will pay royalties earned from product commercialization, although each company will hold rights to developments falling within its area of focus.